Transforming cancer treatment

with oral small-molecule immunotherapies


Karus is a leader in the design and development of innovative small-molecule drugs that combine targeted therapy and immunotherapy activity for the effective treatment of a diverse range of solid and hematological cancers.

We have applied our insights in the structure, biology and function of individual isoforms of PI3K and HDAC enzymes to design and develop innovative new medicines with significant clinical and commercial potential.

Our highly-experienced management team has a track-record of creating, developing and partnering therapeutic programs in Europe and North America.

Based in Oxford, UK, we are a privately-held company with a strong investor base, comprising SV Life Sciences, New Leaf Ventures, Novo A/S and IP Group.